There are about 11304 clinical studies being (or have been) conducted in Denmark. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The aim of this trial was to compare two different uterotomy surgical techniques on the occurrence of a uterine niche and the risk of a number of short- and long-term gynecological complications associated with the presence and size of the niche.
The primary hypothesis is that computed tomography (CT) is superior to invasive coronary angiography (ICA) concerning the primary endpoint MACE (MACE = major adverse cardiovascular event; defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) after a maximum follow-up of 4 years, in other words, that CT will result in a significantly lower rate of MACE. Secondary outcomes include MICE (MICE = minor cardiovascular events), procedural complications, cost-effectiveness, radiation exposure, cross-over to CT or ICA, gender differences, and health-related quality of life.
Preoperative anemia is an independent risk factor for the need for allogeneic transfusion during surgery and increased postoperative morbidity. Treatment of preoperative anemia is recommended. However the type of preoperative anemias in elective hip- and knee surgery has only been sparsely studied. This observational study aims to investigate the incidence and type of anemias prior to elective hip- and knee arthroplasty.
The purpose of the study is to investigate the difference in late radiation morbidity between hypofractionated and normofractionated loco-regional breast irradiation irrespective of mastectomy or lumpectomy. In patients who a candidates for a boost, the boost will be provided as a simultaneous integrated boost.
Despite efficient antiretroviral treatment for HIV infection, decrease in life expectancy remains. Excess mortality is mainly due to non-AIDS co-morbidity including cardiovascular, pulmonary, and liver related diseases. Both HIV-unrelated and HIV-related risk factors probably contribute to this pattern. At present, most evidence regarding co-morbidity in HIV infection rely on cross-study comparisons of HIV-infected persons with published population rates and few prospective studies in U.S. cohorts. Using well characterized participants from the Copenhagen General Population Study (CGPS) as controls, we aim to include >1500 HIV-infected persons in the COCOMO study to determine if co-morbidity is more prevalent or develops at a higher rate in HIV-infected persons. The study will asses 1) cardiovascular, 2) pulmonary and 3) liver-related co-morbidity using uniformly collected data in the two cohorts. The investigators aim to study the relative impact of HIV-unrelated and HIV-related factors on development of co-morbidity.
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors.
After gastric bypass, 10-20% of patients will obtain a suboptimal weight loss, often defined as <50% of the excess body weight. Exaggerated meal related secretion of gut hormones seem important for appetite reduction and subsequent weight loss after gastric bypass, however it is not clear whether different gut hormone responses are responsible for different postoperative weight loss responses. The purpose of the study is to investigate gut hormone secretion, vagal integrity and the effect of octreotide on ad libitum food intake in patients with suboptimal weight loss after gastric bypass and compare results to a matched group of gastric bypass operated patients with high postoperative weight loss but similar age, sex and preoperative BMI.
The purpose of this study is to determine the type of macronutrient (carbohydrate, lipid or protein) that most potently stimulates the endogen secretion of different gut hormones (primary outcome = Glucagon-Like peptide-1) in gastric bypass operated patients. The study also includes a comparison of the secretion of gut hormones after oral intake of lipid with or without a pancreatic lipase inhibitor.
The purpose of this multicentre, prospective study is: - Document the Clinical and Radiographic performance of the stem at 3 months, 1 year, 3 years, 5 years, 7 and 10 years. - Report Safety and Survivorship up to 10 years F/up.
Introduction: Accreditation programmes for healthcare systems have been implemented in more than 70 countries to stimulate high-quality organisational performance. Several Danish healthcare institutions are covered by the Danish Healthcare Quality Programme (DDKM) and all Danish public hospitals have been accredited according to the DDKM since 2010. The dates of each survey are currently being announced 8-10 months beforehand. Announcing surveys has been criticised for creating an "arranged reality". It has therefore been suggested that a national intervention be conducted to evaluate the effect of unannounced hospital surveys. Methods and analysis: All public somatic and psychiatric hospitals in Denmark (n=30) were invited to participate in the trial. Twenty-three hospitals (77%) (3 university hospitals, 5 psychiatric hospitals, and 15 general hospitals) agreed to participate and to be randomised to one of the trial clusters. Eleven hospitals will receive announced surveys (control group) and 12 hospitals will receive unannounced surveys (intervention group).We hypothesise that hospitals receiving unannounced surveys will be rated as less successful than hospitals receiving announced surveys, defined as meeting less compliance with accreditation standards and performance indicators. Nine experienced surveyors employed and educated by The Danish Institute for Quality and Accreditation in Health Care (IKAS) will be responsible for conducting the surveys according to an abbreviated version of the current Danish periodic survey. The outcome is compliance with indicators reflecting organisational performance. Compliance will be analysed using logistic or linear regression analysis with random effects, contingency tables, and Pearson's chi-squared test or Fishers exact test, whichever is most appropriate. Ethics and Dissemination: This trial is pending ethics approval from Research Ethichs Comite for North Denmark Region. The findings from this randomised controlled trial will be disseminated through peer-reviewed journals, national and international conferences and will be utilised as health care political decision making for the future national accreditation programme. In addition, the results will facilitate to validate the effect of unannounced hospital surveys; given the issues of currently meeting an "arranged reality" during hospital surveys, this seems extremely desirable.